Posts

Denis Odinokov – Conquering Cross-Linking for Biomedical Longevity

In order to achieve biomedical longevity, the problem of cross-Linking of the extracellular matrix needs to be addressed. Cells are held together by special linking proteins. When too many cross-links form between cells in a tissue, the tissue can lose its elasticity and cause problems including arteriosclerosis, presbyopia and weakened skin texture. These are chemical bonds between structures that are part of the body, but not within a cell. In senescent people many of these become brittle and weak. Fixing cross-linking may prove more difficult than just removing it – as it may create a vacuum where more waste is pulled in to fill the void left behind. Though some research is being conducted, the problem deserves a lot more hands on deck – and far more funding.
Denis gives a technical explanation of why conquering cross-linking is important, and strategies for addressing this problem in this interview conducted at the Undoing Aging conference in Berlin 2019.

Introduction to Denis’ writing/research here – “The Impact of Extracellular Matrix Proteins Cross-linking on the Aging Process“.

Understanding the consequences of the formation of protein crosslinks requires more attention both from the scientific community and independent researchers who are passionate with regards to the extension of the human lifespan. By doing so, it allows us to level up the playing field where we can create and work on more serious and impactful solutions.

Also see GlycoSENSSENS proposes to further develop small-molecular drugs and enzymes to break links caused by sugar-bonding, known as advanced glycation endproducts, and other common forms of chemical linking.

 

Judith Campisi – Senolytics for Healthy Longevity

I had the absolute privilege of interviewing Judith Campisi at the Undoing Aging conference in Berlin.  She was so sweet and kind – it was really a pleasure to spend time with her discussing senolytics, regenerative medicine, and the anti-aging movement.

 

 

 

Judith Campisi was humble, open minded, and careful not to overstate the importance of senolytics, and rejuvenation therapy in general.  Though she really is someone who has made an absolutely huge impact in anti-aging research.  I couldn’t have said it better than Reason at Fight Aging!

As one of the authors of the initial SENS position paper, published many years ago now, Judith Campisi is one of the small number of people who is able to say that she was right all along about the value of targeted removal of senescent cells, and that it would prove to be a viable approach to the treatment of aging as a medical condition. Now that the rest of the research community has been convinced of this point – the evidence from animal studies really is robust and overwhelming – the senescent cell clearance therapies known as senolytics are shaping up to be the first legitimate, real, working, widely available form of rejuvenation therapy.

Reason – Philosophy Of Anti Aging: Ethics, Research & Advocacy

Reason was interviewed at the Undoing Aging conference in Berlin 2019 by Adam Ford – focusing on philosophy of anti-aging, ethics, research & advocacy. Here is the audio!

And the video:

Topics include philosophical reasons to support anti-aging, high impact research (senolytics etc), convincing existence proofs that further research is worth doing, how AI can help and how human research (bench-work) isn’t being replaced by AI atm or in the foreseeable future, suffering mitigation and cause prioritization in Effective Altruism – how the EA movement sees anti-aging and why it should advocate for it, population effects (financial & public health) of an aging population and the ethics of solving aging as a problem…and more.

Reason is the founder and primary blogger at FightAging.org

Keith Comito on Undoing Ageing

What is the relationship between anti-aging and the reduction of suffering? What are some common objections to the ideas of solving aging? How does Anti-Aging stack up against other cause areas (like climate change, or curing specific diseases)? How can we better convince people of the virtues of undoing the diseases of old age?

Keith Comito, interviewed by Adam Ford at the Undoing Aging 2019 conference in Berlin, discusses why solving the diseases of old age is powerful cause. Note the video of this interview will be available soon. He is a computer programmer and mathematician whose work brings together a variety of disciplines to provoke thought and promote social change. He has created video games, bioinformatics programs, musical applications, and biotechnology projects featured in Forbes and NPR.

In addition to developing high-profile mobile applications such as HBO Now and MLB AtBat, he explores the intersection of technology and biology at the Brooklyn community lab Genspace, where he helped to create games which allow players to direct the motion of microscopic organisms.

Seeing age-related disease as one of the most profound problems facing humanity, he now works to accelerate and democratize longevity research efforts through initiatives such as Lifespan.io.

He earned a B.S. in Mathematics, B.S. in Computer science, and M.S. in Applied Mathematics at Hofstra University, where his work included analysis of the LMNA protein.

Future Day Melbourne 2019

Future Day is nigh – sporting a spectacular line of speakers!

Agenda

5.30Doors open – meet and greet other attendees
5.45Introduction
6.00Drew Berry – “The molecular machines that create your flesh and blood” [abstract]
6.45Brock Bastian – “Happiness, culture, mental illness, and the future self” [abstract]
7.30Lynette Plenderleith: “The future of biodiversity starts now” [abstract]
8.15Panel: Drew Berry, Brock Bastian, Lynette Plenderleith
Join the MeetupFuture Day is on the 21st of March - sporting a spectacular line of speakers ranging from Futurology, Philosophy, Biomedical Animation & Psychology!

Venue: KPMG Melbourne – 727 Collins St [map link] – Collins Square – Level 36 Room 2

Limited seating to about 40, though if there is overflow, there will be standing room.

PLEASE have a snack/drink before you come. Apparently we can’t supply food/drink at KPMG, so eat something beforehand – or work up and appetite…
Afterwards we will sojourn at a local pub for some grub and ale.

I’m looking forward to seeing people I have met before, and some new faces as well.

Drew Berry – Biomedical Animator @ The Walter and Eliza Hall Institute of Medical Research
Brock BastianMelbourne School of Psychological Sciences University of Melbourne

Check out the Future Day Facebook Group, and the Twitter account!

Abstracts

The molecular machines that create your flesh and blood

By Drew Berry – Abstract: A profound technological revolution is underway in bio-medical science, accelerating development of new therapies and treatments for the diseases that afflict us and also transforming how we perceive ourselves and the nature of our living bodies. Coupled to the accelerating pace of scientific discovery is an ever expanding need to explain to the public and develop appreciation of our new biomedical capabilities, to prepare the public for the tsunami of new knowledge and medicines that will impact patients, our families and community.
Drew Berry will present the latest visualisation experiments in creating cinematic movies and real-time interactive 3D molecular worlds, that reveal the current state of the art scientific discovery, focusing on the molecular engines that covert the food you eat into the chemical energy that powers your cells and tissues. Leveraging the incredible power of game GPU technology, vast molecular landscapes can be generated for 3D 360 degree cinema for museum and science centre dome theatres, interactive exploration in VR, and Augmented Reality education via student mobile phones.

 

Happiness, culture, mental illness, and the future self

By Brock Bastian – Abstract: What is the future of human happiness and wellbeing. We are currently treating mental illness at the level of individuals, yet rates of mental illness are not going down, and in some cases continue to rise. I will present research indicating that we need to start to tackle this problem at the level of culture. The cultural values places on particular emotional states may play a role in how people respond to their own emotional worlds. Furthermore, I will present evidence that basic cultural differences in how we explain events, predict the future and understand ourselves may also impact on the effectiveness of our capacity to deal with emotional events. This suggests that we need to begin to take culture seriously in how we treat mental illness. It also provides some important insights into what kind of thinking styles we might seek to promote and how we might seek to understand and shape our future selves. This also has implications for how we might find happiness in a world increasingly characterized by residential mobility, weak ties, and digital rather than face-to-face interaction.

 

The future of biodiversity starts now

By Lynette Plenderleith – Abstract: Biodiversity is vital to our food security, our industries, our health and our progress. Yet never before has the future of biodiversity been so under threat as we modify more land, burn more fossil fuels and transport exotic organisms around the planet. But in the face of catastrophic biodiversity collapse, scientists, community groups and not-for-profits are working to discover new ways to conserve biodiversity, for us and the rest of life on our planet. From techniques as simple as preserving habitat to complex scientific techniques like de-extinction, Lynette will discuss our options for the future to protect biodiversity, how the future of biodiversity could look and why we should start employing conservation techniques now. Our future relies on the conservation of  biodiversity and its future rests in our hands. We have the technology to protect it.

 

Biographies

Dr Drew Berry

Dr Drew Berry is a biomedical animator who creates beautiful, accurate visualisations of the dramatic cellular and molecular action that is going on inside our bodies. He began his career as a cell biologist and is fluent navigating technical reports, research data and models from scientific journals. As an artist, he works as a translator, transforming abstract and complicated scientific concepts into vivid and meaningful visual journeys. Since 1995 he has been a biomedical animator at the Walter and Eliza Hall Institute of Medical Research, Australia. His animations have exhibited at venues such as the Guggenheim Museum, MoMA, the Royal Institute of Great Britain and the University of Geneva. In 2010, he received a MacArthur Fellowship “Genius Grant”.

Recognition and awards

• Doctorate of Technology (hc), Linköping University Sweden, 2016
• MacArthur Fellowship, USA 2010
• New York Times “If there is a Steven Spielberg of molecular animation, it is probably Drew Berry” 2010
• The New Yorker “[Drew Berry’s] animations are astonishingly beautiful” 2008
• American Scientist “The admirers of Drew Berry, at the Walter and Eliza Hall Institute in Australia, talk about him the way Cellini talked about Michelangelo” 2009
• Nature Niche Prize, UK 2008
• Emmy “DNA” Windfall Films, UK 2005
• BAFTA “DNA Interactive” RGB Co, UK 2004

Animation http://www.wehi.tv
TED http://www.ted.com/talks/drew_berry_animations_of_unseeable_biology
Architectural projection https://www.youtube.com/watch?v=m9AA5x-qhm8
Björk video https://www.youtube.com/watch?v=Wa1A0pPc-ik
Wikipedia https://en.wikipedia.org/wiki/Drew_Berry

Assoc Prof Brock Bastian

Brock Bastian is a social psychologist whose research focuses on pain, happiness, and morality.

In his search for a new perspective on what makes for the good life, Brock Bastian has studied why promoting happiness may have paradoxical effects; why we need negative and painful experiences in life to build meaning, purpose, resilience, and ultimately greater fulfilment in life; and why behavioural ethics is necessary for understanding how we reason about personal and social issues and resolve conflicts of interest. His first book, The Other Side of Happiness, was published in January 2018.

 

The Other Side of Happiness: Embracing a More Fearless Approach to Living

Our addiction to positivity and the pursuit of pleasure is actually making us miserable. Brock Bastian shows that, without some pain, we have no real way to achieve and appreciate the kind of happiness that is true and transcendent.

Read more about The Other Side of Happiness

Dr. Lynette Plenderleith

Dr. Lynette Plenderleith is a wildlife biologist by training and is now a media science specialist, working mostly in television, with credits including children’s show WAC!
World Animal Championships and Gardening Australia. Lynette is Chair and Founder of Frogs Victoria, President of the Victorian branch of Australian Science Communicators and occasional performer of live science-comedy. Lynette has a Ph.D from Monash University, where she studied the ecology of native Australian frogs, a Master’s degree in the spatial ecology of salamanders from Towson University in the US and a BSc in Natural Sciences from Lancaster University in her homeland – the UK.
Twitter: @lynplen
Website: lynplen.com

 

 

The Future is not a product

It’s more exciting than gadgets with shiny screens and blinking lights.

Future Day is a way of focusing and celebrating the energy that more and more people around the world are directing toward creating a radically better future.

How should Future Day be celebrated? That is for us to decide as the future unfolds!

  • Future Day could be adopted as an official holiday by countries around the world.
  • Children can do Future Day projects at school, exploring their ideas and passions about creating a better future.
  • Future Day costume parties — why not? It makes at least as much sense as dressing up to celebrate halloween!
  • Businesses giving employees a day off from routine concerns, to think creatively about future projects
  • Special Future Day issues in newspapers, magazines and blogs
  • Use your imagination — that’s what the future is all about!

The Future & You

It’s time to create the future together!

Our aspirations are all too often sidetracked in this age of distraction. Lurking behind every unfolding minute is a random tangent with no real benefit for our future selves – so let’s ritualize our commitment to the future by celebrating it! Future Day is here to fill our attention economies with useful ways to solve the problems of arriving at desirable futures, & avoid being distracted by the usual gauntlet of noise we run every other day. Our future is very important – accelerating scientific & technological progress will change the world even more than it already has. While other days of celebration focus on the past – let’s face the future – an editable history of a time to come – a future that is glorious for everyone.

Videos from Previous Future Day Events / Interviews

The End of Aging

Aging is a technical problem with a technical solution – finding the solution requires clear thinking and focused effort. Once solving aging becomes demonstrably feasible, it is likely attitudes will shift regarding its desirability. There is huge potential, for individuals and for society, in reducing suffering through the use of rejuvenation therapy to achieve new heights of physical well-being. I also discuss the looming economic implications of large percentages of illness among aging populations – and put forward that focusing on solving fundamental problems of aging will reduce the incidents of debilitating diseases of aging – which will in turn reduce the economic burden of illness. This mini-documentary discusses the implications of actually solving aging, as well as some misconceptions about aging.

‘The End of Aging’ won first prize in the international Longevity Film Competition *[1] in 2018.


The above video is the latest version with a few updates & kinks ironed out.

‘The End of Aging’ was Adam Ford’s submission for the Longevity Film Competition – all the contestants did a great job. Big thanks to the organisers of competition, it inspires people to produce videos to help spread awareness and understanding about the importance of ending aging.

It’s important to see that health in old age is desirable at population levels – rejuvenation medicine – repairing the bodies ability to cope with stressors (or practical reversal of the aging process), will end up being cheaper than traditional medicine  based on general indefinite postponement of ill-health on population levels (especially in the long run when rejuvenation therapy becomes efficient).

According to the World Health Organisation:

  1. Between 2015 and 2050, the proportion of the world’s population over 60 years will nearly double from 12% to 22%.
  2. By 2020, the number of people aged 60 years and older will outnumber children younger than 5 years.
  3. In 2050, 80% of older people will be living in low- and middle-income countries.
  4. The pace of population ageing is much faster than in the past.
  5. All countries face major challenges to ensure that their health and social systems are ready to make the most of this demographic shift.
The End of Aging – WHO 1 – 2020 portion of world population over 60 will double
The End of Aging – WHO 2 – Elderly outnumbering Infants
The End of Aging – WHO 3 – Pace of Population Aging Faster than in Past
The End of Aging – WHO 4 – 80 perc elderly in low to middle income countries
The End of Aging – WHO 5 Demographic Shifts

 

Happy Longevity Day 2018! 😀

[1] * The Longevity Film Competition is an initiative by the Healthy Life Extension Society, the SENS Research Foundation, and the International Longevity Alliance. The promoters of the competition invited filmmakers everywhere to produce short films advocating for healthy life extension, with a focus on dispelling four usual misconceptions and concerns around the concept of life extension: the false dichotomy between aging and age-related diseases, the Tithonus error, the appeal to nature fallacy, and the fear of inequality of access to rejuvenation biotechnologies.

Aubrey de Grey – Towards the Future of Regenerative Medicine

Why is aging research important? Biological aging causes suffering, however in recent times there as been surprising progress in stem cell research and in regenerative medicine that will likely disrupt the way we think about aging, and in the longer term, substantially mitigate some of the suffering involved in growing old.
Aubrey de Grey is the Chief Science Officer of SENS Foundation – an organisation focused on going beyond ageing and leading the journey towards  the future of regenerative medicine!  
What will it take to get there?
 


You might wonder why pursue  regenerative medicine ?
Historically, doctors have been racing against time to find cures for specific illnesses, making temporary victories by tackling diseases one by one – solve one disease and another urgency beacons – once your body becomes frail, if you survive one major illness, you may not be so lucky with the next one – the older you get the less capable your body becomes to staving off new illnesses – you can imagine a long line of other ailments fading beyond view into the distance, and eventually one of them will do you in.  If we are to achieve  radical healthy longevity , we need to strike at the fundamental technical problems of why we get frail and more disease prone as we get older.  Every technical problem has a technical solution – regenerative medicine is a class of solutions that seek to keep turning the ‘biological clock’ back rather than achieve short-term palliatives.

The damage repair methodology has gained in popularity over the last two decades, though it’s still not popular enough to attract huge amounts of funding – what might tip the scales of advocacy in damage-repair’s favor?
A clear existence proof such as achieving…

Robust Mouse Rejuvenation

In this interview, Aubrey de Grey reveals the most amount of optimism I have heard him express about the near term achievement of Robust Mouse Rejuvenation.  Previously it’s been 10 years away subject to adequate funding (which was not realised) – now Aubrey predicts it might happen within only 5-6 years (subject to funding of course).  So, what is Robust Mouse Rejuvenation – and why should we care?

For those who have seen Aubrey speak on this, he used to say RMR within 10 years (subject to funding)

Specifically, the goal of RBR is this:  Make normal, healthy two-year old mice (expected to live one more year) live three further years. 

  • What’s the ideal type of mouse to test on and why?  The ideal mouse to trail on is one that doesn’t naturally have a certain kind of congenital disease (that might on average only live 1.5 or 2 years) – because increasing their lifespan might only be a sign that you have solved their particular congenital disease.  The ideal type of mouse is one which lives to 3 years on average, which could die of various things.
  • How many extra years is significant? Consistently increasing mouse lifespan for an extra two years on top of their normal three year lifespans – essentially tripling their remaining lifespan.
  • When, or at what stage of the mice’s life to begin the treatment? Don’t start treating the mice until they are already 2 years old – at a time where they would normally be 2 thirds of the way though their life (at or past middle age) and they would have one more year to live.

Why not start treating the mice earlier?  The goal is to produce sufficiently dramatic results in a laboratory to convince the main-stream gerontology community, such that they would willingly publicly endorse the idea that it is not impossible, but indeed it is only a matter of time before rejuvenation therapy will work in humans – that is to get out there on talk shows and in front of cameras and say all this.

Arguably, the mainstream gerontology community are generally a bit conservative – they have vested interests in being successful in publishing papers, they get grants they have worries around peer review, they want tenure, and have a reputation to uphold.   Gerontologists hold the keys to public trust – they are considered to be the authorities on aging.
When gerontologists are convinced and let the world know about it, a lot of other people in the scientific community and in the general community will also then become convinced.  Once that happens, here’s what’s likely to happen next – longevity through rejuvenation medicine will become a big issue, there will be domino effects – there will be a war on aging, experts will appear on Oprah Winfrey, politicians will have to include the war on aging in their political manifesto if they want to get elected.

Yoda - the oldest mouse ever to have lived?
Yoda, a cute dwarf mouse, was named as the oldest mouse in 2004 at age 4 who lived with the much larger Princess Leia, in ‘a pathogen-free rest home for geriatric mice’ belonging to Dr. Richard Miller, professor of pathology in the Geriatrics Center of the Medical School. “Yoda is only the second mouse I know to have made it to his fourth birthday without the rigors of a severe calorie-restricted diet,” Miller says. “He’s the oldest mouse we’ve seen in 14 years of research on aged mice at U-M. The previous record-holder in our colony died nine days short of his 4th birthday; 100-year-old people are much more common than 4-year-old mice.” (ref)

What about Auto-Immune Diseases?

Auto-immune diseases (considered incurable to some) – get worse with aging for the same reason we loose general ability to fight off infections and attack cancer. Essentially the immune system looses it’s precision – it has two arms: the innate system and the adaptive – the adaptive side works by having polyclonality – a very wide diversity of cells with different rearrangements of parts of the genome that confer specificity of the immune cell to a particular target (which it may or may not encounter at some time in the future) – this polyclonality diminishes over life such that the cells which are targeted towards a given problem with the immune system are on average less precisely adapted towards it – so the immune system takes longer to do it’s job or doesn’t do it effectively – so with autoimmune system it looses it’s ability to distinguish between things that are foreign and things that are part of the body. So this could be powerfully addressed by the same
measures taken to rejuvenate the immune system generally – regenerating the thyamis and illuminating senescent cells that are accumulating in the blood.

Big Bottlenecks

See Aubrey discuss this at timepoint: 38:50
Bottlenecks: which bottlenecks does Aubrey believes need most attention from the community of people who already believe aging is a problem that needs to be solved?

  1. The first thing: Funding. The shortage of funding is still the biggest bottleneck.
  2. The second thing: The need for policy makers to get on board with the ideas and understand what is coming – so it’s not only developing the therapies as quickly as possible, it’s also important that once they are developed, the therapies get disseminated as quick as possible to avoid complete chaos.

It’s very urgent to have proper discussions about this.  Anticipating the anticipation – getting ready for the public anticipating these therapies instead of thinking that it’s all science fiction and is never going to happen.

 

Effective Advocacy

See Aubrey discuss this at timepoint: 42:47
Advocacy, it’s a big ask to get people from extreme opposition to supporting regenerative medicine. Nudging people a bit sideways is a lot earlier – that is getting them from complete offense to less offense, or getting people who are un-decided to be in favor of it.

Here are 2 of the main aspects of advocacy:

  1. feasibility / importance – emphasize progress, embracement by the scientific community (see paper hallmarks of aging – single most highly cited paper on the biology of aging this decade) – defining the legitimacy of the damage repair approach – it’s not just a crazy hair brained idea …
  2. desirability – concerns about (bad arguments : on overpopulation – oh don’t worry we will immigrate into space – the people who are concerned about this problem aren’t the ones who would like to go to space) – focus on more of the things that can generalize to desirable outcomes – so regenerative medicine will have side effects, like a longer lifespan, but also people will be more healthy at any given age compared to what they would be in they hadn’t had regenerative therapy – no body wants Alzheimer’s, or heart disease – if the outcome of regenerative medicine is that then it’s easier to sell.

We need a sense of proportion on possible future problems – will they generally be more serious than they are today?
Talking about uploading, substrate independence, etc one is actively alienating the public – it’s better to create a foundation of credibility in the conversation before you decide to persuade anyone of anything.  If we are going to get from here to the long term future we need advocacy now – the short term matters as well.

More on Advocacy here:

And here

Other Stuff

This interview covers a fair bit of ground, so here are some other points covered:

– Updates & progress at SENS
– Highlights of promising progress in regenerative medicine in general
– Recent funding successes, what can be achieved with this?
– Discussion on getting the message across
– desirability & feasibility of rejuvenation therapy
– What could be the future of regenerative medicine?
– Given progress so far, what can people alive today look forward to?
– Multi-factorial diseases – Fixing amyloid plaque buildup alone won’t cure Alzheimer’s – getting rid of amyloid plaque alone only produced mild cognitive benefits in Alzheimer’s patients. There is still the unaddressed issue of tangles… If you only get rid of one component in a multi-component problem then you don’t get to see much improvement of pathology – in just he same way one shouldn’t expect to see much of an overall increase in health & longevity if you only fix 5 of 7 things that need fixing (i.e. 5 of the 7 strands of SENS)
– moth-balling anti-telomerase approach to fighting cancer in favor of cancer immunotherapy (for the time being) as it’s side effects need to be compensated against…
– Cancer immunotherapy – stimulating the bodies natural ability to attack cancer with it’s immune system -2 approaches – car-T (Chimeric Antigen Receptors and T cells), and checkpoint inhibiting drugs.. then there is training the immune system to identify neoantegens (stuff that all cancers produce)

Biography

Chief Science Officer, SENS Research Foundation, Mountain View, CA – http://sens.org

AgeX Therapeutics – http://www.agexinc.com/

Dr. Aubrey de Grey is a biomedical gerontologist based in Mountain View, California, USA, and is the Chief Science Officer of SENS Research Foundation, a California-based 501(c)(3) biomedical research charity that performs and funds laboratory research dedicated to combating the aging process. He is also VP of New Technology Discovery at AgeX Therapeutics, a biotechnology startup developing new therapies in the field of biomedical gerontology. In addition, he is Editor-in-Chief of Rejuvenation Research, the world’s highest-impact peer-reviewed journal focused on intervention in aging. He received his BA in computer science and Ph.D. in biology from the University of Cambridge. His research interests encompass the characterisation of all the types of self-inflicted cellular and molecular damage that constitute mammalian aging and the design of interventions to repair and/or obviate that damage. Dr. de Grey is a Fellow of both the Gerontological Society of America and the American Aging Association, and sits on the editorial and scientific advisory boards of numerous journals and organisations. He is a highly sought-after speaker who gives 40-50 invited talks per year at scientific conferences, universities, companies in areas ranging from pharma to life insurance, and to the public.

 

Many thanks for reading/watching!

Consider supporting SciFuture by:

a) Subscribing to the SciFuture YouTube channel: http://youtube.com/subscription_cente…

b) Donating – Bitcoin: 1BxusYmpynJsH4i8681aBuw9ZTxbKoUi22 – Etherium: 0xd46a6e88c4fe179d04464caf42626d0c9cab1c6b – Patreon: https://www.patreon.com/scifuture

c) Sharing the media SciFuture creates: http://scifuture.org

Kind regards, Adam Ford – Science, Technology & the Future

Surviving the Zombie Cell Apocalypse – Oisín Biotechs Stephen Hilbert

Oisín Biotechnologies ground-breaking research and technology is demonstrating that the solution to mitigating the effects of age-related diseases is to address the damage created by the aging process itself. We have recently successfully launched our first subsidiary, Oisin Oncology, focusing in combating multiple cancers.

Interview with Stephen Hilbert

We cover the exciting scientific progress at Oisín, targeting senescent cells (dubbed ‘zombie cells’) to help them to die properly, rejuvenation therapy vs traditional approaches to combating disease, Oisín’s potential for aiding astronauts survive high levels of radiation in space, funding for the research and therapy/drug development and specifically Stephen’s background in corporate development in helping raise capital for Oisín and it’s research.


Are we close to achieving Robust Mouse Rejuvenation?

According to Aubrey de Grey we are about 5-6 years away from  robust mouse rejuvenation   (RBR) subject to the kind of funding SENS has received this year and the previous year (2017-2018). There has been progress in developing certain therapies .

Specifically, the goal of RBR is this:

  • Make normal, healthy two-year old mice (expected to live one more year) live three further years.
    • The type of mice: The ideal mouse to trail on is one that doesn’t naturally have a certain kind of congenital disease (that might on average only live 1.5 or 2 years) – because increasing their lifespan might only be a sign that you have solved their particular congenital disease.
    • Number of extra years: Consistently increasing mouse lifespan for an extra two years on top of their normal three year lifespans – essentially tripling their remaining lifespan.
    • When to begin the treatment: Don’t start treating the mice until they are already 2 years old – at a time where they would normally be 2 thirds of the way though their life (at or past middle age) and they would have one more year to live.

Why not start treating the mice earlier?  The goal is to produce sufficiently dramatic results in a laboratory to convince the main-stream gerontology community such that they would willingly publicly endorse the idea that it is not impossible, but indeed it is only a matter of time before rejuvenation therapy will work in humans – that is to get out there on talk shows and in front of cameras and say all this.

The mainstream gerontology community are generally a bit conservative – they have vested interests in being successful in publishing papers, they get grants they have worries around peer review, they want tenure, and have a reputation to uphold.   Gerontologists hold the keys to public trust – they are considered to be the authorities on aging.

 

For the lowdown on progress towards Robust Mouse Rejuvenation see partway through this interview with Aubrey de Grey!

Preliminary results from study showing normalized mouse survival at 140 weeks

Stephen heads up corporate development for Oisín Biotechnologies. He has served as a business advisor to Oisín since its inception and has served on several biotechnology company advisory boards, specializing in business strategy and capital formation. Prior to Oisín, his career spanned over 15 years in the banking industry where he served as trusted advisor to accredited investors around the globe. Most recently he headed up a specialty alternative investment for a company in San Diego, focusing in tax and insurance strategies for family offices and investment advisors. Stephen is the founder of several ventures in the areas of real estate small manufacturing of novelty gifts and strategic consulting. He serves on the Overlake Hospital’s Pulse Board, assists with Children’s Hospital Guild and is the incoming Chairman at the Columbia Tower Club, a member’s club in Seattle.
LinkedIn Profile

Head of Corporate Strategy/Development Pre-Clinical Oisin Biotechnologies and OncoSenX
FightAging - Oisin Biotechnologies Produces Impressive Mouse Life Span Data from an Ongoing Study of Senescent Cell Clearance
FightAging reported:
Oisin Biotechnologies is the company working on what is, to my eyes, the best of the best when it comes to the current crop of senolytic technologies, approaches capable of selectively destroying senescent cells in old tissues. Adding senescent cells to young mice has been shown to produce pathologies of aging, and removal of senescent cells can reverse those pathologies, and also extend life span. It is a very robust and reliable approach, with these observations repeated by numerous different groups using numerous different methodologies of senescent cell destruction. Most of the current senolytic development programs focus on small molecules, peptides, and the like. These are expensive to adjust, and will be tissue specific in ways that are probably challenging and expensive to alter, where such alteration is possible at all. In comparison, Oisin Biotechnologies builds their treatments atop a programmable suicide gene therapy; they can kill cells based on the presence of any arbitrary protein expressed within those cells. Right now the company is focused on p53 and p16, as these are noteworthy markers of cancerous and senescent cells. As further investigation of cellular senescence improves the understanding of senescent biochemistry, Oisin staff could quickly adapt their approach to target any other potential signal of senescence – or of any other type of cell that is best destroyed rather than left alone. Adaptability is a very valuable characteristic. The Oisin Biotechnologies staff are currently more than six months in to a long-term mouse life span study, using cohorts in which the gene therapy is deployed against either p16, p53, or both p16 and p53, plus a control group injected with phosphate buffered saline (PBS). The study commenced more than six months ago with mice that were at the time two years (104 weeks) old. When running a life span study, there is a lot to be said for starting with mice that are already old; it saves a lot of time and effort. The mice were randomly put into one of the four treatment groups, and then dosed once a month. As it turns out, the mice in which both p16 and p53 expressing cells are destroyed are doing very well indeed so far, in comparison to their peers. This is quite impressive data, even given the fact that the trial is nowhere near done yet.
Considering investing/supporting this research?  Get in contact with Oisin here.

The future of neuroscience and understanding the complexity of the human mind – Brains and Computers

Two of the world’s leading brain researchers will come together to discuss some of the latest international efforts to understand the brain. They will discuss two massive initiatives – the US based Allen Institute for Brain Science and European Human Brain Project. By combining neuroscience with the power of computing both projects are harnessing the efforts of hundreds of neuroscientists in unprecedented collaborations aimed at unravelling the mysteries of the human brain.

This unique FREE public event, hosted by ABC Radio and TV personality Bernie Hobbs, will feature two presentations by each brain researcher followed by an interactive discussion with the audience.

This is your chance to ask the big brain questions.

[Event Registration Page] | [Meetup Event Page]

ARC Centre of Excellence for Integrative Brain Function

Monday, 3 April 2017 from 6:00 pm to 7:30 pm (AEST)

Melbourne Convention and Exhibition Centre
2 Clarendon Street
enter via the main Exhibition Centre entrance, opposite Crown Casino
South Wharf, VIC 3006 Australia

Professor Christof Koch
President and Chief Scientific Officer, Allen Institute for Brain Science, USA

Professor Koch leads a large scale, 10-year effort to build brain observatories to map, analyse and understand the mouse and human cerebral cortex. His work integrates theoretical, computational and experimental neuroscience. Professor Koch pioneered the scientific study of consciousness with his long-time collaborator, the late Nobel laureate Francis Crick. Learn more about the Allen Institute for Brain Science and Christof Koch.

Professor Karlheinz Meier
Co-Director and Vice Chair of the Human Brain Project
Professor of Physics, University of Heidelberg, Germany

Professor Meier is a physicist working on unravelling theoretical principles of brain information processing and transferring them to novel computer architectures. He has led major European initiatives that combine neuroscience with information science. Professor Meier is a co-founder of the European Human Brain Project where he leads the research to create brain-inspired computing paradigms. Learn more about the Human Brain Project and Karlheinz Meier.

 

 

This event is brought to you by the Australian Research Council Centre of Excellence for Integrative Brain Function.

Discovering how the brain interacts with the world.

The ARC Centre of Excellence for Integrative Brain Function is supported by the Australian Research Council.

Extending Life is Not Enough

Dr Randal Koene covers the motivation for human technological augmentation and reasons to go beyond biological life extension.

randal_koene_squareCompetition is an inescapable occurrence in the animate and even in the inanimate universe. To give our minds the flexibility to transfer and to operate in different substrates bestows upon our species the most important competitive advantage.” I am a neuroscientist and neuroengineer who is currently the Science Director at Foundation 2045, and the Lead Scientist at Kernel, and I head the organization carboncopies.org, which is the outreach and roadmapping organization for the development of substrate-independent minds (SIM) and also previously participated in the ambitious and fascinating efforts of the nanotechnology startup Halcyon Molecular in Silicon Valley.

Slides of talk online here
Video of Talk:

Points discussed in the talk:
1. Biological Life-Extension is Not Enough Randal A. Koene Carboncopies.org
2. PERSONAL
3. No one wants to live longer just to live longer. Motivation informs Method.
4. Having an Objective, a Goal, requires that you have some notion of success.
5. Creating (intelligent) machines that have the capabilities we do not — is not as good as being able to experience them ourselves… Imagine… creating/playing music. Imagine… being the kayak.Imagine… perceiving the background radiation of the universe.
6. Is being out of the loop really your goal?
7. Near-term goals: Extended lives without expanded minds are in conflict with creative development.
8. Social
9. Gene survival is extremely dependent on an environment — it is unlikely to survive many changes.Worse… gene replication does not sustain that which we care most about!
10. Is CTGGAGTAC better than GTTGACTGAC? We are vessels for that game — but for the last10,000 years something has been happening!
11. Certain future experiences are desirable, others are not — these are your perspectives, the memes you champion…Death keeps stealing our champions, our experts.
12. Too early to do uploading? – No! The big perspective is relevant now. We don’t like myopic thinking in our politicians, lets not be myopic about world issues ourselves.
13. SPECIES
14. Life-extension in biology may increase the fragility of our species & civilization… More people? – Resources. Less births? – Fewer novel perspectives. Expansion? – Environmental limitation.
15. Biological life-extension within the same evolutionary niche = further specialization to the same performance “over-training” in conflict with generalization
16. Aubrey de Grey: Ultimately, desires “uploading”
17. TECHNICAL
18. Significant biological life-extension is incredibly difficult and beset by threats. Reality vs. popular perception.
19. Life-extension and Substrate-Independence are two different objectives
20. Developing out of a “catchment area” (S. Gildert) may demand iterations of exploration — and exploration involves risk.Hard-wired delusions and drives. What would an AGI do? Which types of AGI would exist in the long run?
21. “Uploading” is just one step of many — but a necessary step — for a truly advanced species
22. Thank You carboncopies.orgrandal.a.koene@carboncopies.org

http://www.carboncopies.org/singularity-summit-australia-2012
http://2012.singularitysummit.com.au/2012/11/randal-koene-extending-life-is-not-enough/

There is a short promo-interview for the Singularity Summit AU 2012 conference that Adam Ford did with Dr. Koene, though unfortunately the connection was a bit unreliable, which is noticeable in the video:

Most of those videos are available through the SciFuture YouTube channel: http://www.youtube.com/user/TheRationalFuture

randal-koene-extending-life-is-not-enough